No Data
Watson Pharmaceuticals: Report for the third quarter of 2024
Chongqing Pharscin Pharmaceutical (002907.SZ): The net income for the first three quarters was 74.5768 million yuan, a year-on-year increase of 66.56%.
Gelonghui October 28th | Chongqing Pharscin Pharmaceutical (002907.SZ) announced its third-quarter report for 2024. In the first three quarters of 2024, the company achieved revenue of 0.614 billion yuan, a year-on-year increase of 19.21%; net income attributable to shareholders of the listed company was 74.5768 million yuan, a year-on-year increase of 66.56%; net income after deducting non-recurring gains and losses was 60.0233 million yuan, a year-on-year increase of 60.53%; basic earnings per share were 0.1786 yuan per share.
chongqing pharscin pharmaceutical (002907.SZ) released performance for the first three quarters, with a net income of 74.5768 million yuan, a year-on-year increase of 66.56%.
Chongqing Pharscin Pharmaceutical (002907.SZ) released the third quarter report of 2024, achieving revenue in the first three quarters...
Express News | Chongqing Pharscin Pharmaceutical: Received the notice of re-registration approval for pharmaceuticals.
Express News | Chongqing Pharscin Pharmaceutical: The controlling shareholder plans to reduce its shareholding by no more than 3%.
Chongqing Pharscin Pharmaceutical (002907.SZ): Aluminum magnesium carbonate, quercetin dihydrate injection approved for re-registration.
Gelonghui October 16th, Chongqing Pharscin Pharmaceutical (002907.SZ) announced that the company recently received the "Chemical Raw Materials Re-registration Approval Notice" for one active pharmaceutical ingredient and the "Pharmaceutical Re-registration Approval Notice" for one pharmaceutical issued by the Chongqing Drug Administration. The chemical raw material aluminum magnesium carbonate is used to produce aluminum magnesium carbonate tablets. Quercetin injection is used for ischemic cerebrovascular diseases (such as cerebral thrombosis, cerebral embolism), thrombotic phlebitis, central retinal vein occlusion, and edema caused by increased vascular permeability.
No Data
No Data